Reply
- PMID: 32356932
- DOI: 10.1002/uog.22032
Reply
Comment on
-
Genome-wide cfDNA testing of maternal blood.Ultrasound Obstet Gynecol. 2020 Jan;55(1):13-14. doi: 10.1002/uog.21945. Ultrasound Obstet Gynecol. 2020. PMID: 31894638 No abstract available.
-
Benefit vs potential harm of genome-wide prenatal cfDNA testing requires further investigation and should not be dismissed based on current data.Ultrasound Obstet Gynecol. 2020 May;55(5):695-696. doi: 10.1002/uog.22030. Ultrasound Obstet Gynecol. 2020. PMID: 32356934 No abstract available.
References
-
- van der Meij KRM, Sistermans EA, Macville MVE, Stevens SJC, Bax CJ, Bekker MN, Bilardo CM, Boon EMJ, Boter M, Diderich KEM, et al. TRIDENT-2: National Implementation of Genome-Wide Non-Invasive Prenatal Testing as a First-Tier Screening Test in the Netherlands. Am J Hum Genet 2019; 105: 1091-1101.
-
- Centrum voor Medische Genetica. http://www.brusselsgenetics.be/default.aspx.
-
- Belgian Advisory Committee on Bioethics. Opinion no. 66 of 9 May 2016 on the ethical challenges posed by non-invasive prenatal testing (NIPT) for trisomies 21, 13 and 18. www.health.belgium.be/bioeth.
-
- Abousleiman C, Lismonde A, Jani JC. Concerns following rapid implementation of first-line screening for aneuploidy by cell-free DNA analysis in the Belgian healthcare system. Ultrasound Obstet Gynecol 2019; 53: 847-848.
Publication types
LinkOut - more resources
Full Text Sources